Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion

NCT04502017 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

360

Enrollment

OTHER

Sponsor class

Conditions

Device-Related Thrombosis
Atrial Fibrillation
Left Atrial Appendage Occlusion

Interventions

DRUG: ASA plus Clopidogrel
DRUG: Genetic-Tailored AntiThrombotic Strategy
DRUG: Half-Dose of novel OAC

Sponsor

Texas Cardiac Arrhythmia Research Foundation